VBI Vaccines (Nasdaq: VBIV) (“VBI”) will deliver a presentation, Optimization of the Process for Making Clinical Supplies of an Enveloped Virus-like Particle for Cytomegalovirus, at the Modern Vaccines Adjuvants & Delivery Systems Conference (“MVADS”) on Monday, May 18th, 2015. The event is being held at the Leiden University Medical Center in The Netherlands.
A synopsis of the presentation, which will be delivered by Dr. Marc Kirchmeier, Ph.D., VBI’s Vice President of Formulation Development, will be made available on this current page following the event.
Update: Download the Presentation
VBI’s eVLP vaccine platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines. eVLPs are an innovative new class of synthetic vaccines that are designed to closely resemble the structure of viruses. Because of their structural similarity to viruses found in nature, eVLPs are capable of imparting greater immunity than immunization with the same recombinant target protein alone. VBI is focused first on applying its eVLP technology to develop a prophylactic cytomegalovirus (“CMV”) vaccine.
“Following process improvements and innovations, VBI, with its third-party manufacturers, has demonstrated the ability to manufacture eVLPs at a 50L scale, which in terms of both yield and purity, we expect to be suitable for manufacture at a commercial scale,” said Dr. Kirchmeier. “This is a great stride forward in both our CMV program, and also in demonstrating the potential utility of our eVLP technology in manufacturing other highly potent vaccine and therapeutic candidates.”
With its eVLP technology, VBI has the ability to rationally design a vaccine by including different antigens and controlling their relative expression. However, because of their complexity, manufacturing eVLPs at 50L scale required the development of novel processes and controls, which will be described in VBI’s upcoming presentation.
MVADS, now in its fifth year, is an international conference that provides academic, industrial, governmental, and regulatory groups a forum to share the latest vaccine development strategies and research. To learn more, visit: http://bit.ly/mvads-2015